Lentiviral Vector CDMOs — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
36
CDMOs tracked
36
Fully scored
12
With FDA records
33
FDA inspections
94
EMA/MHRA GMP certs
Shortlist lentiviral vector CDMOs with Signal
CDMO Signal is an independent sourcing platform CAR-T, TCR, and ex vivo gene therapy sponsors use to compare and shortlist lentiviral vector CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then verify BSL-2, RCL, potency, and scale directly with the shortlisted suppliers.
- Compare lentiviral vector CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
- Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your CAR-T, TCR, or ex vivo gene therapy program's shortlisting criteria.
- Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to verify BSL-2 containment, RCL testing, potency, and scale directly.
The top lentiviral vector CDMOs on CDMO Signal's independent composite are Thermo Fisher Scientific, AGC Biologics, and Oxford Biomedica. The Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. Lentiviral vector CDMO selection typically comes down to BSL-2 containment integrity, suspension platform maturity, potency and RCL analytics, and a defensible regulatory record for material that lands in patient-bound cells. Rankings update as new inspection, certificate, and clinical data enters the platform. Full methodology at cdmosignal.com/methodology.
Lentiviral vectors are the workhorse of ex vivo gene therapy — used to engineer T cells for CAR-T, TCR programs, and to modify hematopoietic stem cells for inherited disorders. Because the vector integrates into the genome of patient-bound cells, lentiviral manufacturing carries the regulatory weight of a critical starting material under full GMP, mandatory replication-competent lentivirus (RCL) testing, and BSL-2 containment throughout production.
Selecting a lentiviral vector CDMO comes down to five buyer-critical dimensions: BSL-2 containment maturity and site inspection history on lentivirus specifically, a scalable suspension (or well-run adherent) platform, qualified titer + potency + RCL assays, capacity headroom at your target dose × patient volume, and defensible tech-transfer support. The rankings below score each CDMO on FDA inspection classifications, EMA/MHRA GMP density, ClinicalTrials.gov sponsor breadth, and monitored capacity signals — a composite that reflects the regulatory record and operational depth needed for material that lands in patient-bound cells.
FDA inspection outcomes across these CDMOs: 14 NAI (no action), 19 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (35), United States (29), Denmark (18), Germany (10), France (7).
Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
81.0 | 100.0 | 6 insp · 10 GMP | Available | 2 programs |
| 2 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
78.6 | 100.0 | 2 insp · 23 GMP | Available | 2 programs |
| 3 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
76.2 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 4 |
Lonza
Basel, Switzerland
|
76.0 | 95.7 | 2 insp · 8 GMP | — | 1 programs |
| 5 |
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
|
75.2 | 100.0 | 1 insp · 0 GMP | — | 1 programs |
| 6 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
74.5 | 98.0 | 1 insp · 0 GMP | Available | 9 programs |
| 7 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
90.9 | 98.3 | 8 insp · 11 GMP | Limited | 0 programs |
| 8 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 9 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 10 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
80.2 | 97.1 | 4 insp · 8 GMP | — | 0 programs |
| 11 |
OB
OmniaBio
Hamilton, ON
|
79.5 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 12 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 13 |
BB
bluebird bio Manufacturing
Durham, NC
|
78.5 | — | — | — | 0 programs |
| 14 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 15 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 16 |
ET
Exothera
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 17 |
PG
ProBioGen
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 18 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 19 |
BV
Biovian
Turku, Finland
|
78.0 | 99.8 | 1 insp · 4 GMP | — | 0 programs |
| 20 |
AG2
August Bioservices
San Carlos, CA
|
77.5 | 98.7 | 1 insp · 0 GMP | — | 0 programs |
| 21 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
73.0 | 95.7 | 1 insp · 0 GMP | Limited | 0 programs |
| 22 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 23 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
71.5 | 85.8 | 3 insp · 0 GMP | Available | 0 programs |
| 24 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.3 | — | — | — | 49 programs |
| 25 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 26 |
RA
Recipharm Advanced Bio
Stockholm, Sweden
|
63.0 | — | — | — | 0 programs |
| 27 |
GF
GeneFab
Alameda, CA and South San Francisco
|
61.5 | — | — | Available | 0 programs |
| 28 |
MA
Matica Biotechnology
College Station, TX
|
59.0 | — | — | Available | 0 programs |
| 29 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 30 |
WB
Waisman Biomanufacturing
Madison, WI
|
59.0 | — | — | — | 0 programs |
| 31 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 32 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 33 |
AM
Anemocyte
Gerenzano, IT
|
59.0 | — | — | — | 0 programs |
| 34 |
Vantage Vector (Demo)
Gaithersburg, MD
|
59.0 | — | — | Available | 0 programs |
| 35 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | — | 8 programs |
| 36 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
56.5 | — | — | — | 0 programs |
What to evaluate in a Lentiviral Vector CDMO
Containment & biosafety
Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.
Process platform maturity
Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.
Analytics & potency
Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.
Who are the leading, trusted, and reputable CDMOs for lentiviral vector manufacturing?
The most-cited leaders in independent CDMO Signal Score rankings are the CDMOs that combine three specific signals: (1) dense EMA + MHRA GMP certification specifically covering lentiviral / viral vector manufacturing scope, (2) a clean or well-managed FDA inspection record on the site the vector will run on, and (3) supply history to approved or late-stage CAR-T / cell therapy programs. The top-3 on the composite Signal Score meet all three signals. "Trusted" and "reputable" are subjective; the objective proxies most sponsors use are (a) commercial-approved-product involvement (Kymriah, Yescarta, Breyanzi, bluebird bio's ex vivo programs), (b) inspection classifications on lentiviral suites, and (c) tenure — CDMOs with 5+ years of lentiviral GMP manufacturing carry demonstrated process discipline that newer entrants haven't proved yet. The table above surfaces the objective signals; individual profile pages surface the commercial-program involvement where publicly attributable.
What is the typical lead time for a lentiviral vector CDMO engagement?
Realistic lentiviral CDMO lead times span three phases. Slot reservation and tech transfer from RFP-signed to first process-development batch typically runs 6-12 months for a first-time sponsor, driven by BSL-2 suite availability and analytics platform qualification. Engineering + toxicology runs add 3-6 months. GMP clinical supply — the actual patient-bound material — adds another 4-8 months from tech-transfer completion to first release, depending on lot size, comparability requirements, and platform maturity. Total: sponsors should plan 12-24 months from CDMO signature to first-in-human lot release for a novel lentiviral program. CDMOs with mature suspension platforms and pre-qualified assay panels can compress the early phases; commercial-scale-experienced CDMOs de-risk the final phase. Late-stage tech transfers (Phase 2 → Phase 3) into a new lentiviral CDMO are highly risk-managed events — comparability studies alone can add 6-12 months.
Which lentiviral vector CDMOs handle commercial-scale supply?
Commercial-scale lentiviral vector supply is a genuinely narrow field — fewer than a dozen CDMOs globally have supplied vector to approved or late-stage cell therapies. The commercial-scale lentiviral filter surfaces CDMOs with a top-quartile Signal Score and broad ClinicalTrials.gov sponsor footprint. Leaders on that filter combine dense EMA/MHRA GMP certification with a track record of supplying vector to approved cell therapies (CAR-T commercial programs are the tell). Sponsors weighing commercial supply should verify (1) capacity headroom at commercial batch scale — not just process capability, (2) comparability data across the CDMO's site network — most late-stage programs cannot absorb mid-development tech transfer risk, and (3) commercial supply contracts already in place — a CDMO already supplying commercial vector has demonstrated the operational discipline the pre-approval inspection audits.
How do BSL-2 lentiviral CDMOs differ on containment?
All GMP lentiviral manufacturing runs at BSL-2 with segregated suites, validated decontamination, and replication-competent lentivirus (RCL) testing — but CDMOs differ meaningfully in containment design maturity. Suite architecture: single-product suites (dedicated to one program) vs multi-product suites with campaign-based cleaning differ in risk profile. Change-over validation ranges from swab-and-move to full facility revalidation between products. Site-level inspection history specific to lentivirus is uneven — some CDMOs have clean 483 histories on lentiviral suites, others carry findings that indicate containment weakness. The FDA inspection record shown in the table above is the most objective signal here: CDMOs with clean lentiviral-specific 483 histories have demonstrated containment control under regulator scrutiny. Ask any lentiviral CDMO for the last two inspection reports specifically covering their lentiviral suite before shortlisting.
What are the alternatives to using a lentiviral CDMO?
Sponsors evaluating lentiviral CDMO alternatives typically consider three paths. In-house lentiviral manufacturing: viable for large biotech / big pharma with existing viral vector infrastructure, but the capex + regulatory + hiring lift is 24-36 months and $50-150M realistically — only justified when volume is committed for a decade. Alternative vector platforms: retrovirus (older technology, integration bias trade-offs), AAV (non-integrating, wrong for ex vivo cell engineering in most cases), non-viral delivery (electroporation, lipid nanoparticles for mRNA — increasingly used for in vivo CAR-T but not equivalent to lentivirus for stable ex vivo integration). Academic vector cores: fine for early research but not GMP-compliant, so require a CDMO handoff before IND. For 95% of clinical and commercial lentiviral programs, using a specialized lentiviral CDMO is the correct answer — the rankings above surface which one.
Which lentiviral CDMOs pair vector with cell therapy fill-finish?
Programs needing both lentivirus supply and downstream cell processing benefit from a CDMO — or CDMO group — handling both in-house. Integration cuts tech transfer overhead, aligns release specs across drug substance and drug product, and removes a critical supply-chain seam. Cross-reference the Cell Therapy CDMOs directory; CDMOs appearing in both lentiviral and cell therapy rankings are the integrated candidates worth prioritizing for combined-scope RFPs. Standouts include Lonza (lentivirus + cell therapy across multiple sites), the Catalent group (via Paragon and MaSTherCell heritage), Charles River (multi-platform), and Thermo Fisher (viral vector + cell processing). Point-solution CDMOs (vector-only or cell-only) can be assembled together but add coordination cost — worth it only when a specialized CDMO's process depth outweighs the seam.
How CDMO Signal computes the lentiviral ranking
The lentiviral Signal Score is the platform's standard four-pillar composite. For lentiviral CDMOs specifically, the Quality pillar (35%) weights FDA inspection classifications (NAI, VAI, OAI) and EMA/MHRA GMP certificate density — both proxies for the containment-and-comparability track record that matters most in this modality. Operations (25%) reflects ClinicalTrials.gov sponsor breadth for programs matched to the CDMO. Financial Stability (20%) draws on SEC filings and parent-company health — critical for lentiviral because supply continuity risk destroys clinical timelines. Capacity Intelligence (20%) tracks monitored trade press for facility expansions and capacity additions. Full weightings, source lists, and edge cases at cdmosignal.com/methodology.
Lentiviral Vector CDMOs — Frequently Asked Questions
Who are the top Lentiviral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include Thermo Fisher Scientific, AGC Biologics, Oxford Biomedica. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Lentiviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 12 Lentiviral Vector CDMOs with FDA inspection records and 94 EMA/MHRA GMP certificates across the group.
What should I look for in a lentiviral vector CDMO?
Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.
How is lentiviral vector manufacturing different from AAV?
Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.
Related modalities